139
H, Yoshimura N. Improved visualization of polypoidal choroidal
vasculopathy lesions using spectral-domain optical coherence
tomography. Retina 2009; 29 (1): 52-59.
31. Kameda T, Tsujikawa A, Otani A, Sasahara M, Gotoh N, Tamura
H, Yoshimura N. Polypoidal choroidal vasculopathy examined
with en face optical coherence tomography. Clin Experiment
Ophthalmol 2007; 35 (7): 596-601.
32. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka
S, Matsushita R. Causes of macular serous retinal detachments in
Japanese patients 40 years and older. Retina 2009; 29 (3): 395-404.
33. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic
polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10 (1):
1-8.
34. Ozawa S, Ishikawa K, Ito Y, Nishihara H, Yamakoshi T, Hatta
Y, Terasaki H. Differences in macular morphology between
polypoidal choroidal vasculopathy and exudative age-related
macular degeneration detected by optical coherence tomography.
Retina 2009; 29 (6): 793-802.
35. Moorthy RS, Lyon AT, Rabb MF, Spaide RF, Yannuzzi LA, Jampol
LM. Idiopathic polypoidal choroidal vasculopathy of the macula.
Ophthalmology 1998; 105 (8): 1380-1385.
36. Guyer DR, Yannuzzi LA, Ladas I, Slakter JS, Sorenson JA, Orlock
D. Indocyanine green-guided laser photocoagulation of focal
spots at the edge of plaques of choroidal neovascularization. Arch
Ophthalmol 1996; 114 (6): 693-697.
37. Gomez-Ulla F, Gonzalez F, Torreiro MG. Diode laser
photocoagulation in idiopathic polypoidal choroidal vasculopathy.
Retina 1998; 18 (5): 481-483.
38. YuzawaM,MoriR,HaruyamaM.Astudyoflaserphotocoagulation
for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2003;
47 (4): 379-384.
39. Yamanishi A, Kawamura A, Yuzawa M. Laser photocoagulation
for idiopathic polypoidal choroidal vasculopathy. Jpn J Clin O
1998; 52: 1691-1694.
40. Nishijima K, Takahashi M, Akita J, Katsuta H, Tanemura
M, Aikawa H, Mandai M, Takagi H, Kiryu J, Honda Y. Laser
photocoagulation of indocyanine green angiographically identified
feeder vessels to idiopathic polypoidal choroidal vasculopathy. Am
J Ophthalmol 2004; 137 (4): 770-773.
41. Mitamura Y, Kubota-Taniai M, Okada K, Kitahashi M, Baba
T, Mizunoya S, Yamamoto S. Comparison of photodynamic
therapy to transpupillary thermotherapy for polypoidal choroidal
vasculopathy. Eye (Lond) 2009; 23 (1): 67-72.
42. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y,
Ikuno Y, Tano Y. One-year outcomes of photodynamic therapy
in age-related macular degeneration and polypoidal choroidal
vasculopathy in Japanese patients. Ophthalmology 2008; 115 (1):
141-146.
43. Mauget-Faysse M, Quaranta-El MM, De La ME, Leys A.
Photodynamic therapy with verteporfin in the treatment of
exudative idiopathic polypoidal choroidal vasculopathy. Eur J
Ophthalmol 2006; 16 (5): 695-704.
44. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong
TH. Photodynamic therapy with verteporfin for symptomatic
polypoidal choroidal vasculopathy: one-year results of a prospective
case series. Ophthalmology 2004; 111 (8): 1576-1584.
45. Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. Long-term follow-
up of polypoidal choroidal vasculopathy after photodynamic
therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol
2007; 245 (10): 1569-1571.
46. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Two-
year visual outcomes after photodynamic therapy in age-related
macular degeneration patients with or without polypoidal
choroidal vasculopathy lesions. Retina 2009; 29 (7): 960-965.
47. Silva Leal S, Silva Rufino, Figueira J, Cachulo ML, Pires I, Faria de
Abreu JR, Cunha-Vaz JG. Photodynamic therapy with verteporfin
in polypoidal choroidal vasculopathy: Results after 3 years of
follow-up. Retina 2009; in Press.
48. Lee WK, Lee PY, Lee SK. Photodynamic therapy for polypoidal
choroidal vasculopathy: vaso-occlusive effect on the branching
vascular network and origin of recurrence. Jpn J Ophthalmol
2008; 52 (2): 108-115.
49. Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. Long-term follow-
up of polypoidal choroidal vasculopathy after photodynamic
therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol
2007; 245 (10): 1569-1571.
50. Shiraga F, Matsuo T, Yokoe S, Takasu I, Okanouchi T, Ohtsuki H,
Grossniklaus HE. Surgical treatment of submacular hemorrhage
associated with idiopathic polypoidal choroidal vasculopathy. Am
J Ophthalmol 1999; 128 (2): 147-154.
51. Fujii GY, Pieramici DJ, Humayun MS, Schachat AP, Reynolds
SM, Melia M, De Juan E Jr. Complications associated with
limited macular translocation. Am J Ophthalmol 2000; 130 (6):
751-762.
52. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal
bevacizumab (Avastin) with or without photodynamic therapy
for the treatment of polypoidal choroidal vasculopathy. Br J
Ophthalmol 2008; 92 (5): 661-666.
53. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-
Feijoo J, Leila M, Garcia-Sanchez J. Short-term anatomic effect
of ranibizumab for polypoidal choroidal vasculopathy. Eur J
Ophthalmol 2008; 18 (4): 645-648.
54. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-
Feijoo J, Leila M, Garcia-Sanchez J. Short-term anatomic effect
of ranibizumab for polypoidal choroidal vasculopathy. Eur J
Ophthalmol 2008; 18 (4): 645-648.
55.
-
6-month-results-from-EVEREST-study-evaluating-Visudyne-R-
therapy-in-patients-with-polypoidal-13292269/. Accessed March
31, 2010.
